Hims & Hers Stock Plunges 27%
This is a Ozempic news story, published by Insider, that relates primarily to FDA news.
Ozempic news
For more Ozempic news, you can click here:
more Ozempic newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsInsider news
For more news from Insider, you can click here:
more news from InsiderAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Hers stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest semaglutide news, stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
FDAInsider
•Health
Health
Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
82% Informative
Hims & Hers' revenue grew by 69% in 2024 , with GLP-1 drugs representing about 15% of sales.
Last week , the FDA removed semaglutide, the active ingredient in Ozempic , from its shortage list.
The FDA allows for the sale of compounded versions of drugs on the shortage list to limit patient supply issues.
VR Score
86
Informative language
87
Neutral language
51
Article tone
semi-formal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
2
Source diversity
1
Affiliate links
no affiliate links